MetaCap

Cognition Therapeutics (CGTX) vs Tenaya Therapeutics (TNYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cognition Therapeutics (CGTX) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 58.1% versus a loss of 76.7%. Over five years, CGTX leads with a -93.5% price change compared with -98.5% for TNYA. Tenaya Therapeutics is the larger company by market cap ($65.3 million vs $55.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGTX-58.12%TNYA-76.70%
+35%-24%-82%
Nov 21, 20251 yearNov 20, 2026
CGTX-94.35%TNYA-98.68%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGTX versus TNYA key metrics
MetricCGTXTNYA
Share price$0.5822$0.2866
Market cap$55.37M$65.32M
1-day change-3.06%-3.99%
YTD return-56.87%-59.75%
1-year return-58.12%-76.70%
5-year return-93.47%-98.50%
EPS (TTM)$-0.16$-0.48
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-23.49M$-90.60M
52-week high$1.81$1.46
52-week low$0.55$0.28
Distance from 52-week high-67.83%-80.37%
Analyst consensusstrong_buynone
Avg. price target upside+471.97%+1016.54%
Average volume464.94K2.96M
Shares outstanding95.10M227.93M
Employees1470
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGTX has outperformed TNYA by 18.6 percentage points over the past year.

About Cognition Therapeutics

CGTX stock →

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About Tenaya Therapeutics

TNYA stock →

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees

CGTX vs TNYA FAQ

Which is bigger, Cognition Therapeutics or Tenaya Therapeutics?

Tenaya Therapeutics (TNYA) is larger, with a market capitalization of $65.32M compared with $55.37M for Cognition Therapeutics (CGTX).

Which stock has performed better over the past year, CGTX or TNYA?

CGTX returned -58.12% over the past 12 months, compared with -76.70% for TNYA (price return, excluding dividends). Past performance does not predict future results.

Are Cognition Therapeutics and Tenaya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons